Intraperitoneal chemotherapy for prevention and treatment of peritoneal carcinomatosis from colorectal origin

Annals of Gastroenterology

Volumn 16, Issue 1, 2003, Pages 20-33

  de Breen, E ^a,b   Zoetmulder, F A N ^a   Romanos, J ^b   Witkamp, A J ^a   Tsiftsis, D D ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; TOPOTECAN; TUMOR NECROSIS FACTOR;

ABDOMINAL MASS; ABDOMINAL PAIN; ABDOMINAL SURGERY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG TUMOR LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PATIENT SELECTION; PERITONEUM METASTASIS; POSTOPERATIVE CARE; REVIEW; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 30844455918     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potential curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol 1988; 6:106-118.
2. Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum 1991; 34:723-727.
3. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol 1983; 22:95-99.
4. Tong D, Russell AH, Dawson LE, et al. Adenocarcinoma of the cecum: natural history and clinical patterns of recurrence following radical surgery. Int J Radiat Oncol Biol Phys 1983; 9:357-360.
5. Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983; 9:361-365.
6. Tong D, Russell AH, Dawson LE, Wisbeck W. Second laparotomy for proximal colon cancer. Sites of recurrence and implications for adjuvant therapy. Am J Surg 1983; 145:382-386.
7. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994; 37(suppl):S115-S122.
8. Zoetmulder FAN. Cancer cell seeding during abdominal surgery. Experimental studies. In Sugarbaker PH (ed): "Peritoneal carcinomatosis: Principles of management." Boston: Kluwer Academic Publishers, 1996:155-161.
9. Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112:1096-1102.
10. Schott A, Vogel I, Krueger U, et al. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 1998; 227:372-379.
11. Solomon MJ, Egan M, Roberts RA, Philips J, Russell P. Incidence of free colorectal cancer cells on the peritoneal surface. Dis Colon Rectum 1997; 40:1294-1298.
12. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63:364-367.
13. Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358-363.
14. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80:1179-1187.
15. Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 1997; 21:748-762.
16. Clark JW. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Sem Oncol 1997; 24(suppl 18):S18-S24.
17. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353:391-399.
18. Benson AB 3rd: Therapy for advanced colorectal cancer. Sem Oncol 1998; 25(suppl 11):2-11.
19. Nobile MT, Rosso R, Sertoli MR, et al. Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992; 28A:1823-1827.
20. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-1418
21. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7:1419-1426.
22. Piedbois P, Buyse M, Rustum Y, et al. Modulation of fluorouracil by leucovorin in advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10:896-903.
23. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbeck's Arch Surg 1999; 384:576-587.
24. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14:254-261.
25. Sugarbaker PH. Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy. J Surg Oncol 1991; suppl 2:36-41.
26. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 1985; 12:23-28.
27. Freedman RS, Lenzi R, Kudelka AP, et al. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 1998; 4:121-140.
28. van Ravenswaay Claasen HH, Eggermont AMM. Intraperitoneal immunotherapy of cancer: A review of options for treatment. Cancer Treat Res 1996; 82:13-40.
29. Herrera-Ornelas L, Petrelli NJ, Mittelman A, Dougherty TJ, Boyle DG. Photodynamic therapy in patients with colorectal cancer. Cancer 1986; 57:677-684.
30. Sindelar WF, DeLaney TF, Tochner Z, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Arch Surg 1991; 126:318-324.
31. DeLaney TF, Sindelar WF, Tochner Z, et al. Phase-1 study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993; 25:445-447.
32. Harlow SP, Rodriguez-Bigas M, Mang T, Petrelli NJ. Intraoperative photodynamic therapy as an adjunct to surgery for recurrent rectal cancer. Ann Surg Oncol 1995; 2:228-232.
33. Hendren S, Hahn S, Spitz F, et al. Phase II study trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors [abstract]. In Society of Surgical Oncology Cancer Symposium annual meeting program; 2000, March 16-19, 2000, New Orleans:29. Abstract 84.
34. Witkamp AJ, de Bree E, van Goethem A, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365-374.
35. Markman M. Intraperitoneal chemotherapy. Sem Oncol 1991; 18:248-254.
36. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996; 82:53-63.
37. Kuzuya T, Yamauchi M, Ito A, et al. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994; 46:685-689.
38. Guichard S, Chatelut E, Lochon I, et al. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998; 42:165-170.
39. Pestieau SR, Belliveau JF, Griffin H, et al. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 2001; 76:106-114.
40. Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): Pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol 2000; 26:696-700.
41. Marayama M, Nagahama T, Yuasa Y. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis. Anticancer Res 1999; 19:4187-4191.
42. Kelsen DP, Saltz L, Cohen AM et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer 1994; 74:222-233.
43. Muggia FM, Chan KK, Russell C, et al. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine. Cancer Chemother Pharmacol 1991; 28:241-250.
44. Hofstra LS, Bos AM, de Vries EG. et al. A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer 2001; 85:1627-1633.
45. Speyer JL, Sugarhaker PH, Collins JM, et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981; 41:1916-1922.
46. Hagiwara A, Sakakura C, Shirasu M, Yamasaki J, Togawa T. Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanonia in mice. Anticancer Drugs 1998; 9:287-289.
47. Fujimoto S, Takahashi M, Kobayashi K, et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology 1993; 50:338-343.
48. van der Vaart PJM, van der Vange N, Zoetmulder FAN, et al. Intraperitoncal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34:148-154.
49. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209-3214.
50. McVie JG, Dikhoff T, Van der Heide J et al. Tissue concentration of platinum after intraperitoneal cisplatinum administration in patients. Proc Am Assoc Cancer Res 1985; 26:162.
51. Panteix G, Guillaumont M, Cherpin L, et al. Study of the pharmakokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 1993; 50:366-370.
52. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221:29-42.
53. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30:233-280.
54. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseuclomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997; 2:197-226.
55. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955; 159:1704-1707.
56. Markman M. Tntraperitoneal chemotherapy of ovarian cancer. Semin Oncol 1998; 25:356-360.
57. Averbach AM, Sugarbaker PH. Methodologic considerations in treatment using intraperitoneal chemotherapy. In Sugarbaker PH (ed): "Peritoneal carcinomatosis: Principles of management." Boston: Kluwer Academic Publishers, 1996:289-309.
58. Graf W, Westlin JE, Pahlman L, et al. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin plus systemic 5-fluorouracil after colorectal cancer surgery: randomized phase II placebo-controlled study. Int J Colorectal Dis 1994; 9:35-39.
59. Dunnick NR, Jones RB, Doppmen JL, et al. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 1979; 133:221-223.
60. Ash SR. Peritoneal access devices for intraperitoneal chemotherapy: Cancer Treat Res 1996; 82:387-413.
61. Piccart MJ, Speyer JL, Markman M, et al. Intraperitoneal chemotherapy: technical experience at five institutions. Sem Oncol 1985; 3(suppl 4):90-96.
62. Topuz E. Salihoglu Y, Aydiner A, et al. Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol 2000; 74:223-226.
63. Topuz E, Saip P, Aydiner A, et al. Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol 1998; 19:775-279.
64. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001; 47:269-276.
65. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998; 77:1349-1354.
66. Sugarbaker PH, Gianola FJ, Spreyer JL, et al. Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary color or rectal cancer. Surgery 1985; 98:414-421.
67. Vaillant J-C, Nordlinger B, Deuffic S, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer. A multicenter phase III trial. Ann Surg 2000; 231:449-456.
68. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999; 26:536-539.
69. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221:124-132.
70. Gianola FJ, Sugarbaker PH, Barofsky I, White DE, Meyers CE. Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Am J Clin Oncol 1986; 9:403-410.
71. Horsell KW, Merten S, Clingan P, King DW, Morris DL. Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. Aust N Z J Surg 1999; 69:729-732.
72. Culliford AT 4th, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8:787-795.
73. Fumagalli U, Trabucchi E, Soligo M, et al. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Surg Res 1991; 50:82-87.
74. van der Kolk BM, de Man BM, Wobbes T, Hendriks T. Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine? Br J Cancer 1999; 79:545-550.
75. Fukuchi SG, Seeburger JL, Parquet G, Rolandelli RH. Influence of 5-fluorouracil on colonic healing and expression of transforming growth factor-beta 1. J Surg Res 1999; 84:121-126.
76. Kanellos I, Odisseos C, Zaraboukas T, et al. Colonic healing after early intraperitoneal administration of 5-fluorouracil and interferon in rats. Int J Colorectal Dis 1997; 12:45-48.
77. Fata F, Ron IG, Maluf F, Klimstra D, Kemeny N. Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines. Cancer 2000; 88:2447-2251.
78. de Bree E, Witkamp AJ, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79: 46-61.
79. Cavaliere F, Di Filippo F, Cosinalli M et al. The integrated experience of peritonea' carcinomatosis. A preliminary experience. J Exp Clin Cancer Res 1999; 18:151-158.
80. Elias D, Dube P, Blot F et al. Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. Eur J Surg Oncol 1997; 23:317-321.
81. Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20:585-592.
82. Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction inticaperitoneal chemotherapy. Cancer Treat Res 1996; 82:317-325.
83. Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer 1996; 32A:1727-1733.
84. Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin N Am 1989; 27:621-7.
85. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998; 41:147-154.
86. Benoit L, Duvillard C, Rat P, Chauffert B. Effects de la temperature intra-abdominale sur la diffuion tissulaire et tumorale du cisplatine intraperitoneal dansun modele de carcinose peritoneale chez le rat. Chirurgie 1999; 124:375-379.
87. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40:256-260.
88. Fujimoto S, Shrestha RD, Kokobun M, et al. Intraperitoneal hyperthermic perfusion combined with, surgery for gastric cancer with peritoneal seeding. Ann Surg 1988: 208:536-541.
89. Fujimoto S, Shrestha RD, Kokobun M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990; 212:592-596.
90. Fujimara T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990; 65:65-71.
91. Yonemura Y, Fujimara T, Fushida S, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991; 15:530-536.
92. Kokobun M, Fujimoto S, Shrestha RD, et al. Intraperitoneal hyperthermic perfusion treatment for gastric cancer and peritoneal implantation. Reg Cancer Treat 1991; 3:316-319.
93. Yonemura Y, Fujimara T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119:437-444.
94. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79:884-891.
95. Sayag-Beuajard AC, Francois Y, Glehen O, et al. Intraperitoneal chemohyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res 1999; 19:1375-1382.
96. Sebbag J, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87:1587-1593.
97. de Bree E, Christodoulakis M, Tsiftsis D. Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy. Ann Oncol 2000; 11:753-756.
98. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458-463.
99. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin-C. Cancer 1988; 61:232-237.
100. Fujimara T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18:150-155.
101. Hamazoe R, Maeta M, Kaibara N. Intraoperative thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73:2048-2052.
102. Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995; 161:581-586.
103. Yonemura Y, Ninomiya I, Kaiji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 1995; 19:450-455.
104. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85:529-534.
105. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000; 87:1006-1015.
106. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77:2622-2629.
107. Yamaguchi A, Tsukioka Y, Fushida S et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancer. Dis Colon Rectum 1992; 35:964-968.
108. Nishimura G, Fushida S, Fujimura T, Yonemura Y, Miwa K, Miyazaki I. Intraperitoneal treatment for peritoneal dissemination of colorectal cancer. Reg Cancer Treat 1996; 9:60-2.
109. Schneebaum S, Arnold MW, Staubus A, et al. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 1996; 3:44-50.
110. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin. Eur J Cancer 2001; 37:979-984.
111. Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with Mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepato-Gastroenterol 1994; 41:124-129.
112. Fuzun M, Elverdi B, Avci G, Sokman S, Haciyanli M. Cytoreductive approach to peritoneal carcinomatosis from adenocarcinoma of the large bowel (report of 8 cases). Reg Cancer Treat 1996-1998; 9:223-226.
113. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol; 1999:727-731.
114. Loggie BW, Fleming RA, McQuellen RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561-568.
115. Beaujard AC, Glehen O, Caillot JL et al. Intraperitoneal chemohyperthermia with-mitomycin C for digestive tract cancer with peritoneal carcinomatosis. Cancer 2000; 88:2512-2519.
116. Cavaliere F, Perri P, Di Filippo F, et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000; 74:41-44.
117. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83:1251-1261.
118. Fujimura T, Yonemura Y, Fujita H, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999; 84:60-66.
119. Mansvelt B, Bertrand Cl, Nockerman P, et al. Etude de toxicite et resultats de la chimio-hyperthermie intra-peritoneale chez 28 patients en carcinose peritoneale. Ann Chir 1997; 51:60-67.
120. Piso P, Bektas H, Werner, et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001; 27:286-290.
121. Ellas D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76
122. Tsiftsis D, de Bree E, Romanos J, et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 1999; 134:545-549.
123. Elias D, Antoun S, Goharin A, et al. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig 2000; 1:431-439.
124. Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 1996; 7:596-603.
125. Haller DG. Chemotherapy in gastrointestinal malignancies. Semin Oncol 1988; 15(suppl 4):50-64.
126. Witkamp AJ, van Coevorden F, Kaag MM, et al. Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin [abstract]. Eur J Surg Oncol 1998; 24:214.
127. Fujimoto S, Shrestha RD, Kokobun M, et al. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 1989; 2:198-202.
128. Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early post-operative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 1998; 55:130-138.
129. Loggie BW, Fleming RA. Complications of heated intraperitoneal chemotherapy and strategies for prevention. Cancer Treat Res 1996; 82:221-233.
130. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6:790-796.
131. Fujimoto S, Takahashi M, Endoh F, et al. A clinical pilot study combining surgery whh intraoperative pelvic hyperthermochemotherapy to prevent the local recurrence of rectal cancer. Ann Surg 1991; 213:43-47.
132. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43(suppl):S15-S25.